Guided Therapeutics Secures $700,000 Order from Chinese Distributor for LuViva Systems
Reuters
Jun 10
Guided Therapeutics Secures $700,000 Order from Chinese Distributor for LuViva Systems
Guided Therapeutics Inc. has announced a significant new contract, receiving a $700,000 purchase order and initial payment from its new Chinese distributor, Hangzhou Dongye Medical Technology Company Ltd (HDMT). The order consists of 35 LuViva Advanced Cervical Scan systems, which will be assembled and tested by Guided Therapeutics' partner, Shandong Yaohua Medical Instrument Corporation. HDMT, based in Hangzhou City, is the exclusive provider of gynecology products for 42 hospitals in Zhejiang Province, where approximately two million cervical cancer screenings are conducted annually. Yang Dongye, CEO of HDMT, expressed the company's goal to eventually replace current screening tests with LuViva. Guided Therapeutics plans to begin shipments next month, marking a significant step in expanding LuViva's presence in the region.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guided Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610216570) on June 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.